Viking Therapeutics closes $287.5M public offering of 19.8M shares at $14.50/share

Viking Therapeutics, Inc.

Gross proceeds of approximately $287.5 million from 19,828,300 shares at $14.50 per share.
Underwriters' option to purchase 2,586,300 additional shares exercised in full.
Net proceeds to fund VK2809, VK2735, VK0214 programs and general corporate purposes.
William Blair & Co. served as lead book-runner; Raymond James as joint book-runner.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.